Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 6/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | EYA2 | O00167 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883728 | 1.00 | KMT2A (0.41) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL2501976 | 0.91 | KMT2A (0.36) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL2501975 | 0.91 | KMT2A (0.36) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL28416919 | 0.90 | KMT2A (0.40) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL6285017 | 0.90 | KMT2A (0.40) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL307102 | 0.86 | KMT2A (0.42) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL31040664 | 0.85 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CASP3 | |
| SCHEMBL21838102 | 0.85 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CASP3 | |
| SCHEMBL17108591 | 0.85 | KMT2A (0.44) | KMT2AFABP5FABP7TLR2EPHX2 | |
| SCHEMBL28414420 | 0.85 | KMT2A (0.46) | KMT2AFABP5FABP7TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112592940-B | Biological enzyme synthesis method of N- (9-fluorenylmethoxycarbonyl) -decylaminoacetaldehyde | 江西邦泰绿色生物合成生态产业园发展有限公司 | 2023-05-02 | — | — | CN | claimed |
| CN-107619432-B | Glycopeptide derivative and pharmaceutically acceptable salt, preparation method and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2023-03-17 | — | — | CN | claimed |
| CN-107629115-B | Purification method of telavancin | 福建省微生物研究所 | 2021-05-07 | — | — | CN | claimed |
| CN-107629116-B | Purification method of telavancin | 福建省微生物研究所 | 2021-05-07 | — | — | CN | claimed |
| CN-111233713-A | Synthesis method of telavancin intermediate | 福建康鸿生物科技有限公司 | 2020-06-05 | — | — | CN | claimed |
| CN-107629115-A | A kind of purification process of Te Lawan stars | 福建省微生物研究所 | 2018-01-26 | — | — | CN | claimed |
| CN-107629116-A | A kind of purification process of Te Lawan stars | 福建省微生物研究所 | 2018-01-26 | — | — | CN | claimed |
| EP-3450450-B1 | VANCOMYCIN DERIVATIVE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2025-08-27 | — | — | EP | disclosed |
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | MELINTA SUBSIDIARY CORP. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240165100-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | MELINTA SUBSIDIARY CORP. | 2024-05-23 | — | — | US | disclosed |
| CN-110891590-B | Glycopeptide derivative compound and use thereof | 英斯麦德公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-112592940-B | Biological enzyme synthesis method of N- (9-fluorenylmethoxycarbonyl) -decylaminoacetaldehyde | 江西邦泰绿色生物合成生态产业园发展有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-112592940-B | Biological enzyme synthesis method of N- (9-fluorenylmethoxycarbonyl) -decylaminoacetaldehyde | 江西邦泰绿色生物合成生态产业园发展有限公司 | 2023-05-02 | — | — | CN | disclosed |
| US-6444786-B1 | BACTERICIDES | ADVANCED MEDICINE, INC. | 2002-09-03 | — | — | US | disclosed |
| US-6392012-B1 | COMPOUND FOR USE IN TREATMENT AND PREVENTION OF BACTERIAL INFECTION | ADVANCED MEDICINE, INC. | 2002-05-21 | — | — | US | disclosed |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | CUMBERLAND PHARMACEUTICALS INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2001098328-A2 | GLYCOPEPTIDE PHOSPHONATE DERIVATIVES | THERAVANCE, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| EP-1140993-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Advanced Medicine, Inc. (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001057071-A2 | GLYCOPEPTIDE DERIVATIVES HAVING ANTIBIOTIC ACTIVITY | ADVANCED MEDICINE, INC. (US) | 2001-08-09 | — | — | WO | disclosed |
| WO-2000039156-A1 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ADVANCED MEDICINE, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036219-B2 | Methods of treating infections in overweight and obese patients using antibiotics | NCEH1, NRDC, LPL | KMT2A 3253/4885FABP5 601/4885FABP7 1587/4885 |
| US-20240165100-A1 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS | CLPP, MGAM, MMP8 | KMT2A 3154/4885FABP5 458/4885FABP7 1808/4885 |
| US-20020022590-A1 | Useful as antibiotics; reduced tissue accumulation and/or nephrotoxicity when administered to a mammal; useful against vancomycin-resistant microorganisms | GLS, PIGS, PAG1 | KMT2A 4773/4885FABP5 1107/4885FABP7 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.